Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMOYS8A)

Drug Name

PTG-300 Drug Info

Synonyms

Rusfertide; Rusfertide [USAN]; UNII-XM71MYX0IQ; XM71MYX0IQ; PTG-300FB; WHO 11456; 1628323-80-7; Isovaleryl-Asp-Thr-His-Phe-Pro-cyclo(Cys-Ile-Lys(palm-gamma-Glu)- Phe-Glu-Pro-Arg-Ser-Lys-Gly-Cys)-Lys-NH2

Indication

Disease Entry	ICD 11	Status	REF
Hemochromatosis	5C64.1Y	Phase 2	[1]
Polycythemia vera	2A20.4	Phase 2	[2]

Cross-matching ID

PubChem CID: 155884410
CAS Number: CAS 1628323-80-7
TTD Drug ID: DMOYS8A

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hepcidin (HAMP)	TTPCG5T	HEPC_HUMAN	Replacement	[3]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Hepcidin (HAMP)	DTT	HAMP	10.14	3.018	4.372	4.315

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Hemochromatosis

ICD Disease Classification

5C64.1Y

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Hepcidin (HAMP)	DTT	HAMP	5.37E-01	0.18	0.47

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT04202965) PTG-300 in Subjects With Hereditary Hemochromatosis. U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT04767802) PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit. U.S. National Institutes of Health.
3	Clinical pipeline report, company report or official report of Protagonist Therapeutics.